Business Context and Reporting Period
Company: Gossamer Bio, Inc. (GOSS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2025
Event: Unregistered Sales of Equity Securities (Item 3.02)
On September 24, 2025, Gossamer Bio entered into an Option Agreement and Plan of Merger and Reorganization with Prana Bio, Inc. (owner of Respira Therapeutics, Inc.). This agreement grants Gossamer Bio the right, but not the obligation, to acquire Respira via a merger.
Key Financial Metrics and Transaction Details
This filing reports a specific equity transaction rather than standard periodic financial performance metrics (revenue, profit, cash flow). The filing text does not provide clear values for revenue, profit, margins, or debt.
| Transaction Component | Details |
|---|---|
| Initial Consideration | Issuance of 2,500,000 shares of Common Stock to Prana Bio. |
| Exercise Consideration | Agreement to issue up to 1,500,000 additional shares upon exercise of the merger option. |
| Milestone Consideration | Potential issuance of up to ~6,688,964 additional shares plus cash payments upon achieving regulatory and sales milestones. |
| Option Expiration | Earlier of December 31, 2027, or completion of certain Respira development activities. |
Material Changes and Unusual Items
The primary material change is the potential dilution of existing shareholders due to the issuance of equity for the acquisition option. The transaction is structured as an option to acquire, meaning the full equity issuance is contingent upon the exercise of the option and the achievement of future milestones.
- Unregistered Sale: Shares were issued in reliance upon Section 4(a)(2) of the Securities Act of 1933.
- Contingent Liability: Future cash and stock payments are tied to unspecified regulatory and sales milestones.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future earnings. The primary risk disclosed is the potential dilution of share ownership if the merger option is exercised and milestones are met. The transaction remains subject to the terms and conditions of the Agreement and may be terminated earlier.
Investor Verification Checklist
- Verify the current share count to assess the immediate dilution impact of the 2,500,000 shares issued.
- Review the full "Option Agreement and Plan of Merger and Reorganization" to understand the specific development activities required to trigger the option expiration.
- Confirm the specific regulatory and sales milestones that would trigger the issuance of up to ~6.7 million additional shares.
- Monitor Nasdaq filings for any subsequent updates regarding the exercise of the merger option or termination of the agreement.